DexCom (NASDAQ:DXCM) Insider Sells $1,926,432.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,756 shares of DexCom stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $72.00, for a total value of $1,926,432.00. Following the completion of the transaction, the insider owned 355,726 shares of the company’s stock, valued at approximately $25,612,272. This represents a 7.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

NASDAQ DXCM opened at $73.02 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The business’s 50 day moving average price is $69.27 and its 200-day moving average price is $68.39. The company has a market cap of $28.18 billion, a P/E ratio of 31.21, a P/E/G ratio of 1.22 and a beta of 1.45. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the business posted $0.32 earnings per share. The business’s revenue was up 15.0% compared to the same quarter last year. Sell-side analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current year.

Analysts Set New Price Targets

DXCM has been the topic of a number of research analyst reports. Barclays restated an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Citigroup reissued a “buy” rating and issued a $84.00 price objective (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. TD Cowen restated a “buy” rating and issued a $95.00 target price (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Robert W. Baird set a $80.00 target price on shares of DexCom in a research report on Friday, May 1st. Finally, William Blair raised shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $84.88.

Hedge Funds Weigh In On DexCom

Institutional investors have recently made changes to their positions in the company. Paladin Wealth LLC increased its position in DexCom by 17.4% during the 2nd quarter. Paladin Wealth LLC now owns 9,338 shares of the medical device company’s stock valued at $629,000 after purchasing an additional 1,386 shares during the period. Arista Wealth Management LLC purchased a new stake in shares of DexCom in the 2nd quarter worth approximately $337,000. Sax Wealth Advisors LLC lifted its position in shares of DexCom by 46.1% in the 2nd quarter. Sax Wealth Advisors LLC now owns 17,001 shares of the medical device company’s stock worth $1,068,000 after purchasing an additional 5,364 shares during the period. Hennion & Walsh Asset Management Inc. boosted its stake in shares of DexCom by 2.4% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 14,350 shares of the medical device company’s stock valued at $966,000 after purchasing an additional 340 shares in the last quarter. Finally, Gradient Investments LLC boosted its stake in shares of DexCom by 16.7% during the second quarter. Gradient Investments LLC now owns 372,542 shares of the medical device company’s stock valued at $25,091,000 after purchasing an additional 53,283 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.